Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties.
Advanced glycosylation end products (AGE) of proteins accumulate in the vasculature with diabetes and aging, and are thought to be associated with vascular complications. This led us to examine the interaction of AGE-BSA as a prototype of this class of nonenzymatically glycosylated proteins subjected to further processing, with endothelium. Incubation of 125I-AGE-BSA with cultured bovine endothelium resulted in time-dependent, saturable binding that was half-maximal at a concentration of approximately 100 nM. Although unlabeled normal BSA was not a competitor, unlabeled AGE-BSA was an effective competitor of 125I-AGE-BSA-endothelial cell interaction. In addition, AGE modification of two alternative proteins, hemoglobin and ribonuclease, rendered them inhibitors of 125I-AGE-BSA binding to endothelium, although the native, unmodified forms of these proteins were not. At 37 degrees C, binding of 125I-AGE-BSA or gold-labeled AGE-BSA was followed by internalization and subsequent segregation either to a lysosomal compartment or to the endothelial-derived matrix after transcytosis. Exposure of endothelium to AGE-BSA led to perturbation of two important endothelial cell homeostatic properties, coagulant and barrier function. AGE-BSA downregulated the anticoagulant endothelial cofactor thrombomodulin, and induced synthesis and cell surface expression of the procoagulant cofactor tissue factor over the same range of concentrations that resulted in occupancy of cell surface AGE-BSA binding sites. In addition, AGE-BSA increased endothelial permeability, resulting in accelerated passage of an inert macromolecular tracer, [3H]inulin, across the monolayer. These results indicate that AGE derivatives of proteins, potentially important constituents of pathologic vascular tissue, bind to specific sites on the endothelial cell surface and modulate central endothelial cell functions. The interaction of AGE-modified proteins with endothelium may play an important role in the early stages of increased vascular permeability, as well as vessel wall-related abnormalities of the coagulation system, characteristic of diabetes and aging.
Esposito
C
C
Department of Physiology, Rover Physiology Laboratories, Columbia University-College of Physicians and Surgeons, New York, New York 10032.
Gerlach
H
H
Brett
J
J
Stern
D
D
Vlassara
H
H
D008841:Actin Cytoskeleton / Q000648:ultrastructure; D000818:Animals; D001777:Blood Coagulation; D002417:Cattle; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism*; D017127:Glycation End Products, Advanced; D006023:Glycoproteins / Q000378:metabolism*; D006031:Glycosylation; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D010539:Permeability; D011485:Protein Binding; D011956:Receptors, Cell Surface / Q000378:metabolism; D018179:Receptors, Thrombin; D012709:Serum Albumin / Q000378:metabolism*; D012710:Serum Albumin, Bovine; D013925:Thromboplastin / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000093423:Glycated Serum Albumin
D017127:Glycation End Products, Advanced; D006023:Glycoproteins; D011956:Receptors, Cell Surface; D018179:Receptors, Thrombin; D012709:Serum Albumin; D014409:Tumor Necrosis Factor-alpha; D012710:Serum Albumin, Bovine; D013925:Thromboplastin; D000093423:Glycated Serum Albumin